Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Regorafenib as Second-Line Systemic Therapy May Change the Treatment Strategy and Management Paradigm for Hepatocellular Carcinoma.

Literature DB >> 27781196

Regorafenib as Second-Line Systemic Therapy May Change the Treatment Strategy and Management Paradigm for Hepatocellular Carcinoma.

M Kudo¹.
1. Editor Liver Cancer.

Abstract

Entities: Chemical Disease

Year: 2016 PMID： 27781196 PMCID： PMC5075814 DOI： 10.1159/000449335

Source DB: PubMed Journal: Liver Cancer ISSN： 1664-5553 Impact factor: 11.740

× No keyword cloud information.

22 in total

1. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.

Authors: Jordi Bruix; Won-Young Tak; Antonio Gasbarrini; Armando Santoro; Massimo Colombo; Ho-Yeong Lim; Vincenzo Mazzaferro; Reiner Wiest; María Reig; Andrea Wagner; Luigi Bolondi
Journal: Eur J Cancer Date: 2013-06-25 Impact factor: 9.162

Review 2. Subclassification of BCLC B Stage Hepatocellular Carcinoma and Treatment Strategies: Proposal of Modified Bolondi's Subclassification (Kinki Criteria).

Authors: Masatoshi Kudo; Tadaaki Arizumi; Kazuomi Ueshima; Toshiharu Sakurai; Masayuki Kitano; Naoshi Nishida
Journal: Dig Dis Date: 2015-10-21 Impact factor: 2.404

3. Validation of the criteria of transcatheter arterial chemoembolization failure or refractoriness in patients with advanced hepatocellular carcinoma proposed by the LCSGJ.

Authors: Tadaaki Arizumi; Kazuomi Ueshima; Hirokazu Chishina; Masashi Kono; Masahiro Takita; Satoshi Kitai; Tatsuo Inoue; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Toshiharu Sakurai; Naoshi Nishida; Masatoshi Kudo
Journal: Oncology Date: 2014-11-22 Impact factor: 2.935

Review 4. JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan.

Authors: Masatoshi Kudo; Osamu Matsui; Namiki Izumi; Hiroko Iijima; Masumi Kadoya; Yasuharu Imai; Takuji Okusaka; Shiro Miyayama; Kaoru Tsuchiya; Kazuomi Ueshima; Atsushi Hiraoka; Masafumi Ikeda; Sadahisa Ogasawara; Tatsuya Yamashita; Tetsuya Minami; Koichiro Yamakado
Journal: Liver Cancer Date: 2014-10 Impact factor: 11.740

Review 5. Image-Guided Ablation of Malignant Liver Tumors: Recommendations for Clinical Validation of Novel Thermal and Non-Thermal Technologies - A Western Perspective.

Authors: Riccardo Lencioni; Thierry de Baere; Robert C Martin; Charles W Nutting; Govindarajan Narayanan
Journal: Liver Cancer Date: 2015-10-21 Impact factor: 11.740

6. Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Portal Vein Thrombosis: Impact of Early Response to 4 Weeks of Treatment.

Authors: Chen-Chun Lin; Chien-Fu Hung; Wei-Ting Chen; Shi-Ming Lin
Journal: Liver Cancer Date: 2015-10-15 Impact factor: 11.740

7. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

Authors: Josep M Llovet; Thomas Decaens; Jean-Luc Raoul; Eveline Boucher; Masatoshi Kudo; Charissa Chang; Yoon-Koo Kang; Eric Assenat; Ho-Yeong Lim; Valerie Boige; Philippe Mathurin; Laetitia Fartoux; Deng-Yn Lin; Jordi Bruix; Ronnie T Poon; Morris Sherman; Jean-Frédéric Blanc; Richard S Finn; Won-Young Tak; Yee Chao; Rana Ezzeddine; David Liu; Ian Walters; Joong-Won Park
Journal: J Clin Oncol Date: 2013-08-26 Impact factor: 44.544

8. Post-progression survival and progression-free survival in patients with advanced hepatocellular carcinoma treated by sorafenib.

Authors: Takeshi Terashima; Tatsuya Yamashita; Noboru Takata; Hidetoshi Nakagawa; Tadashi Toyama; Kuniaki Arai; Kazuya Kitamura; Taro Yamashita; Yoshio Sakai; Eishiro Mizukoshi; Masao Honda; Shuichi Kaneko
Journal: Hepatol Res Date: 2015-11-02 Impact factor: 4.288

9. Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization.

Authors: Sadahisa Ogasawara; Tetsuhiro Chiba; Yoshihiko Ooka; Naoya Kanogawa; Tenyu Motoyama; Eiichiro Suzuki; Akinobu Tawada; Fumihiko Kanai; Masaharu Yoshikawa; Osamu Yokosuka
Journal: Oncology Date: 2014-09-06 Impact factor: 2.935

10. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Authors: Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail
Journal: Cancer Res Date: 2004-10-01 Impact factor: 13.312

12 in total

1. Molecular Targeted Agents for Hepatocellular Carcinoma: Current Status and Future Perspectives.

Authors: M Kudo
Journal: Liver Cancer Date: 2016-12-15 Impact factor: 11.740

2. A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib.

Authors: Masatoshi Kudo
Journal: Liver Cancer Date: 2017-03-09 Impact factor: 11.740

3. Cabozantinib as a Second-Line Agent in Advanced Hepatocellular Carcinoma.

Authors: Masatoshi Kudo
Journal: Liver Cancer Date: 2018-04-17 Impact factor: 11.740

4. Lenvatinib May Drastically Change the Treatment Landscape of Hepatocellular Carcinoma.

Authors: Masatoshi Kudo
Journal: Liver Cancer Date: 2018-02-15 Impact factor: 11.740

5. Surrogacy of Time to Progression for Overall Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors: Takeshi Terashima; Tatsuya Yamashita; Tadashi Toyama; Kuniaki Arai; Kazunori Kawaguchi; Kazuya Kitamura; Taro Yamashita; Yoshio Sakai; Eishiro Mizukoshi; Masao Honda; Shuichi Kaneko
Journal: Liver Cancer Date: 2018-06-14 Impact factor: 11.740

6. Efficacy and safety of sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a two-center study in China.

Authors: Shao-Hua Ren; Zi-Lin Cui; Meng-Ran Lang; Qiang Li; Wei Zhang; Feng Fang; Qiang Wu; Yun-Long Cui; Hui-Kai Li; Ping Chen; Yamin Zhang; Tianqiang Song
Journal: J Gastrointest Oncol Date: 2022-06

Review 7. Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit/Risk Assessment.

Authors: Fabio Piscaglia; Sadahisa Ogasawara
Journal: Liver Cancer Date: 2018-01-12 Impact factor: 11.740